10:43 AM EDT, 10/01/2024 (MT Newswires) -- Aytu BioPharma ( AYTU ) and Lupin's Lupin Pharma Canada unit said Tuesday that they have signed a collaborative, distribution and supply agreement for Aytu's two extended-release tablets for treating attention deficit hyperactivity disorder.

The agreement covers Adzenys XR-ODT and Cotempla XR-ODT product lines in Canada, according to the joint statement. Cotempla is a bioequivalent to Adderall XR.

Lupin said it will seek local regulatory and marketing authorizations for both drugs, which are already approved by the US Food and Drug Administration, in the next 18 to 24 months.

Price: 2.32, Change: -0.03, Percent Change: -1.32